Anavex Life Sciences Corp (OTCMKTS:AVXL) recently made a spectacular move up off its $0.20 base to highs of $1.67 a share followed by some significant consolidation since.

AVXL continue to lead the OTCBB in volume and gains and the Company is sitting on drugs in development that could potentially turn the multi-billion dollar Alzheimer’s market upside down.

Anavex Life Sciences Corp (OTCMKTS:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system (CNS) diseases such as Alzheimer’s disease, pain and various types of cancer.

According to fool.com ”Americans are spending $226 billion annually to treat the symptoms of Alzheimer’s disease, and other dementias, rather than the cause of this disease itself. That’s an endlessly frustrating revelation that if left unchecked, could pose a big threat to the healthcare system. According to the Alzheimer’s Association, Alzheimer’s disease could cost Americans $1.1 trillion — yes, trillion — by 2050.

So there is no cure for Alzheimer’s disease, just 4 FDA approved drugs perscribed and sold on the market to treat the symptoms, not the cause.

What makes Anavex such an exciting story is the Company is not focused on treating the symptoms of Alzheimer’s but rather is focused on the root cause which is believed to be protein misfolding. AVXL’s Anavex 2-73 can work as an agonist for the sig-1R receptor that is behind protein misfolding. What is even more exciting is the fact that the same mechanism can work in Parkinson’s and Huntington diseases.

AVXL lead drug candidates, Anavex 2-73 and Anavex PLUS, a combination of Anavex 2-73 and donepezil (Aricept®) are currently being evaluated in a Phase 2a clinical trial for Alzheimer’s disease and continue to be the major catalyst here.

In earlier preclinical studies, Anavex 2-73 showed potential to halt and/or reverse Alzheimer’s disease. Additionally, positive preclinical data reveals the potential for Anavex 2-73 as a platform drug to treat additional CNS disorders, including epilepsy.

To Find out the inside Scoop on AVXL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Anavex began life as Thrifty Printing, a digital to photo print business targeting corner stores that didn’t work out. In 2007 the Company announced it has acquired a portfolio of three patents and one patent application covering drug candidates intended to be further developed through commercialization targeting the areas of neurological diseases and cancer. The patents were assigned by Dr. Alexandre Vamvakides who became CEO of the Company. Years later with Dr. Alexandre Vamvakides long gone there may still be a patent dispute according to Kanak Kanti who has covered AVXL for SA.

The Anavex story really took off when Dr Christopher Missling took over as CEO; he quickly assembled a team of big pharma and biotech experts, doubled the number of Scientific Advisors which is mostly Medical Doctors and raised a company’s record amount of $10M in one funding transaction which means that AVXL is now fully funded going forward.

CEO Dr Christopher Missling (who has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking) recently said “We are pleased with our progress to date. Our Phase 2a clinical trial of ANAVEX 2-73 for the treatment of Alzheimer’s disease is progressing on schedule, with PART A expected to be completed by the end of the year. Additionally, we are expanding PART B, the extension period, from 26 to 52 weeks based on positive initial clinical data and at the request of study participants. In parallel, we are conducting preclinical work with other disease indications including Parkinson’s, which is being funded by a grant from the Michael J. Fox Foundation for Parkinson’s Research.”

Recent Achievements include: On August 12, 2015, Anavex announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Pat. App. No. 14/205,637 related to Anavex 2-73. Upon issuance, the patent will provide intellectual property protection until at least 2030.

On August 10, 2015, Anavex announced that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop Anavex 2-73 for the treatment of Parkinson’s disease. The MJFF grant is expected to fully fund a preclinical study worth $286,456 on the effect of Anavex 2-73 in a Parkinson’s disease animal model.

On July 22, 2015, Anavex announced initial Phase 2a study data for Anavex 2-73, the Company’s lead investigational oral treatment for Alzheimer’s targeting sigma-1 and muscarinic receptors, which is believed to reduce protein misfolding including reduction of beta amyloid, tau and inflammation. Anavex 2-73 showed positive cognitive effects in 83 percent (10/12) of patients during PART A of the study, which consists of a 36-day on-off-on not-yet-optimized dosing regimen to assess bioavailability. At day 36, the amplitude of the cognitive EEG/ERP biomarker P300 increased 38 percent from baseline. Published data suggests that a 38 percent increase is approximately four times higher than donepezil (Aricept(R)), the current standard of care, in the same timeframe.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $104 million market valuation AVXL has $7 million in the treasury and is fully funded going forward with Phase 2a. This is one penny stock that has got everyone’s attention; the Company is sitting on drugs in development that could potentially turn the multi-billion dollar Alzheimer’s market upside down. And its not just Alzheimer’s, Anavex 2-73 could work for Parkinson’s and Huntington diseases as well. The science behind Anavex is compelling the implications of which could be enormous from current price levels. We will be updating on AVXL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with AVXL.

Disclosure: we hold no position in AVXL either long or short and we have not been compensated for this article.